Hepatic Encephalopathy Treatment Alternatives

First-Line Treatment

The American Association for the Study of Liver Diseases recommends lactulose as the first-choice treatment for both initial treatment and prevention of recurrent episodes of hepatic encephalopathy, with a risk ratio of 0.44 (95% CI: 0.31-0.64) compared to placebo 1, 2
Lactulose should be titrated to achieve 2-3 soft bowel movements per day, typically starting with 25 mL every 1-2 hours until bowel movements are produced, then reducing to maintenance dose 1, 4

The American Association for the Study of Liver Diseases recommends neomycin as an alternative when lactulose and rifaximin cannot be used, with important limitations due to risks of ototoxicity, nephrotoxicity, and neurotoxicity 5

L-Ornithine L-Aspartate (LOLA) may be used intravenously in patients who don't respond to conventional therapy, as recommended by the American Association for the Study of Liver Diseases 1, 5
Branched-chain amino acids (BCAAs) have shown improvement in manifestations of minimal hepatic encephalopathy in meta-analyses, according to the American College of Gastroenterology 1

The treatment algorithm for hepatic encephalopathy recommends lactulose as the first-line treatment, with rifaximin added if lactulose alone fails, and neomycin considered if rifaximin is unavailable or contraindicated 1, 2, 3

The American Association for the Study of Liver Diseases recommends always identifying and treating precipitating factors for hepatic encephalopathy as the first priority in management 1, 2, 3
Regular monitoring of renal function is essential when using neomycin due to nephrotoxicity risk, as recommended by the American Association for the Study of Liver Diseases 5